Psychobiotics Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others), By Form (Powder, Liquid/Fluid, Tablets, Others), By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others), By Region and Competition
Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.
A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.
Increasing Demand for Probiotics to Treat Anxiety and Depression
By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.
Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines—a pattern connected to the control of intestinal permeability—probiotics also assist in reducing systemic inflammation.
Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.
Surge in Cases of Anxiety and Depression
The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.
The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.
Rising Consumer Awareness
The market’s growth is also anticipated to be fueled by the psychobiotic capacity to improve the body’s general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.
According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.
In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.
Market Segmentation
Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.
Company Profiles
Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.
Report Scope:
In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.
Increasing Demand for Probiotics to Treat Anxiety and Depression
By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.
Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines—a pattern connected to the control of intestinal permeability—probiotics also assist in reducing systemic inflammation.
Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.
Surge in Cases of Anxiety and Depression
The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.
The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.
Rising Consumer Awareness
The market’s growth is also anticipated to be fueled by the psychobiotic capacity to improve the body’s general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.
According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.
In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.
Market Segmentation
Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.
Company Profiles
Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.
Report Scope:
In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Psychobiotics Market, By Psychotropic Agent:
- Streptococcus
- Bifidobacterium
- Lactobacillus
- Clostridium
- Others
- Psychobiotics Market, By Form:
- Powder
- Liquid/Fluid
- Tablets
- Others
- Psychobiotics Market, By Application:
- Stress Management
- Mood Health & Mood Upliftment
- Depression
- Anxiety
- Sleep Problems
- Others
- Psychobiotics Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Sweden
- Poland
- Slovakia
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- Taiwan
- Malaysia
- Singapore
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
4.1. Brand Awareness
4.2. Preferred Mode of Purchase
4.3. Major Factors Contributing to Mental Illness
4.4. Willingness towards Psychobiotics Consumption
4.5. Commonly Observed Psychological Effect Post Consumption
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. PATENTS ANALYSIS
7. GLOBAL PSYCHOBIOTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Product Market Map
7.3.1. By Psychotropic Agent
7.3.2. By Form
7.3.3. By Application
7.3.4. By Region
7.4. Pricing Analysis
8. NORTH AMERICA PSYCHOBIOTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
8.2.4. By Country
8.3. Pricing Analysis
8.4. North America: Country Analysis
8.4.1. United States Psychobiotics Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value & Volume
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Psychotropic Agent
8.4.1.2.2. By Form
8.4.1.2.3. By Application
8.4.1.3. Pricing Analysis
8.4.2. Mexico Psychobiotics Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value & Volume
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Psychotropic Agent
8.4.2.2.2. By Form
8.4.2.2.3. By Application
8.4.2.3. Pricing Analysis
8.4.3. Canada Psychobiotics Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value & Volume
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Psychotropic Agent
8.4.3.2.2. By Form
8.4.3.2.3. By Application
8.4.3.3. Pricing Analysis
9. EUROPE PSYCHOBIOTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
9.2.4. By Country
9.3. Pricing Analysis
9.4. Europe: Country Analysis
9.4.1. France Psychobiotics Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value & Volume
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Psychotropic Agent
9.4.1.2.2. By Form
9.4.1.2.3. By Application
9.4.1.3. Pricing Analysis
9.4.2. Germany Psychobiotics Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value & Volume
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Psychotropic Agent
9.4.2.2.2. By Form
9.4.2.2.3. By Application
9.4.2.3. Pricing Analysis
9.4.3. United Kingdom Psychobiotics Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value & Volume
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Psychotropic Agent
9.4.3.2.2. By Form
9.4.3.2.3. By Application
9.4.3.3. Pricing Analysis
9.4.4. Italy Psychobiotics Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value & Volume
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Psychotropic Agent
9.4.4.2.2. By Form
9.4.4.2.3. By Application
9.4.4.3. Pricing Analysis
9.4.5. Spain Psychobiotics Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value & Volume
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Psychotropic Agent
9.4.5.2.2. By Form
9.4.5.2.3. By Application
9.4.5.3. Pricing Analysis
9.4.6. Sweden Psychobiotics Market Outlook
9.4.6.1. Market Size & Forecast
9.4.6.1.1. By Value & Volume
9.4.6.2. Market Share & Forecast
9.4.6.2.1. By Psychotropic Agent
9.4.6.2.2. By Form
9.4.6.2.3. By Application
9.4.6.3. Pricing Analysis
9.4.7. Poland Psychobiotics Market Outlook
9.4.7.1. Market Size & Forecast
9.4.7.1.1. By Value & Volume
9.4.7.2. Market Share & Forecast
9.4.7.2.1. By Psychotropic Agent
9.4.7.2.2. By Form
9.4.7.2.3. By Application
9.4.7.3. Pricing Analysis
9.4.8. Slovakia Psychobiotics Market Outlook
9.4.8.1. Market Size & Forecast
9.4.8.1.1. By Value & Volume
9.4.8.2. Market Share & Forecast
9.4.8.2.1. By Psychotropic Agent
9.4.8.2.2. By Form
9.4.8.2.3. By Application
9.4.8.3. Pricing Analysis
10. ASIA-PACIFIC PSYCHOBIOTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
10.2.4. By Country
10.3. Pricing Analysis
10.4. Asia-Pacific: Country Analysis
10.4.1. China Psychobiotics Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Psychotropic Agent
10.4.1.2.2. By Form
10.4.1.2.3. By Application
10.4.1.3. Pricing Analysis
10.4.2. India Psychobiotics Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Psychotropic Agent
10.4.2.2.2. By Form
10.4.2.2.3. By Application
10.4.2.3. Pricing Analysis
10.4.3. South Korea Psychobiotics Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Psychotropic Agent
10.4.3.2.2. By Form
10.4.3.2.3. By Application
10.4.3.3. Pricing Analysis
10.4.4. Japan Psychobiotics Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value & Volume
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Psychotropic Agent
10.4.4.2.2. By Form
10.4.4.2.3. By Application
10.4.4.3. Pricing Analysis
10.4.5. Australia Psychobiotics Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value & Volume
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Psychotropic Agent
10.4.5.2.2. By Form
10.4.5.2.3. By Application
10.4.5.3. Pricing Analysis
10.4.6. Taiwan Psychobiotics Market Outlook
10.4.6.1. Market Size & Forecast
10.4.6.1.1. By Value & Volume
10.4.6.2. Market Share & Forecast
10.4.6.2.1. By Psychotropic Agent
10.4.6.2.2. By Form
10.4.6.2.3. By Application
10.4.6.3. Pricing Analysis
10.4.7. Malaysia Psychobiotics Market Outlook
10.4.7.1. Market Size & Forecast
10.4.7.1.1. By Value & Volume
10.4.7.2. Market Share & Forecast
10.4.7.2.1. By Psychotropic Agent
10.4.7.2.2. By Form
10.4.7.2.3. By Application
10.4.7.3. Pricing Analysis
10.4.8. Singapore Psychobiotics Market Outlook
10.4.8.1. Market Size & Forecast
10.4.8.1.1. By Value & Volume
10.4.8.2. Market Share & Forecast
10.4.8.2.1. By Psychotropic Agent
10.4.8.2.2. By Form
10.4.8.2.3. By Application
10.4.8.3. Pricing Analysis
11. SOUTH AMERICA PSYCHOBIOTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
11.2.4. By Country
11.3. Pricing Analysis
11.4. South America: Country Analysis
11.4.1. Brazil Psychobiotics Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Psychotropic Agent
11.4.1.2.2. By Form
11.4.1.2.3. By Application
11.4.1.3. Pricing Analysis
11.4.2. Argentina Psychobiotics Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Psychotropic Agent
11.4.2.2.2. By Form
11.4.2.2.3. By Application
11.4.2.3. Pricing Analysis
11.4.3. Colombia Psychobiotics Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Psychotropic Agent
11.4.3.2.2. By Form
11.4.3.2.3. By Application
11.4.3.3. Pricing Analysis
12. MIDDLE EAST AND AFRICA PSYCHOBIOTICS MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
12.2.4. By Country
12.3. Pricing Analysis
12.4. MEA: Country Analysis
12.4.1. South Africa Psychobiotics Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Psychotropic Agent
12.4.1.2.2. By Form
12.4.1.2.3. By Application
12.4.1.3. Pricing Analysis
12.4.2. Saudi Arabia Psychobiotics Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Psychotropic Agent
12.4.2.2.2. By Form
12.4.2.2.3. By Application
12.4.2.3. Pricing Analysis
12.4.3. UAE Psychobiotics Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Psychotropic Agent
12.4.3.2.2. By Form
12.4.3.2.3. By Application
12.4.3.3. Pricing Analysis
13. MARKET DYNAMICS
13.1. Drivers
13.1.1. Increased Use of Probiotics for Anxiety and Depression
13.1.2. Surge in Subjects with Anxiety and Depression
13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
13.2. Challenges
13.2.1. Detrimental Effects on Physical Health
13.2.2. Endocrine and Metabolic Side Effects
13.2.3. Unavailability in Developing Countries and Under-Developed Countries
14. MARKET TRENDS & DEVELOPMENTS
14.1. Increasing Number of Clinical Trials
14.2. Increased Competition and Upcoming Innovations
14.3. Mergers & Acquisitions
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. InnovixLabs
15.6.2. Bened Biomedical Co., Ltd
15.6.3. Nutrimmun GmbH
15.6.4. Kerry Group Plc.
15.6.5. Sabinsa Corporation
15.6.6. Lallemand Health Solutions Inc.
15.6.7. DuPont de Nemours, Inc.
15.6.8. Uplift Food Pty Ltd.
15.6.9. Nature's Bounty Co. Ltd.
15.6.10. BioGaia Group
15.6.11. The Life Extension Foundation
15.6.12. Lifted Naturals
16. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
4.1. Brand Awareness
4.2. Preferred Mode of Purchase
4.3. Major Factors Contributing to Mental Illness
4.4. Willingness towards Psychobiotics Consumption
4.5. Commonly Observed Psychological Effect Post Consumption
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. PATENTS ANALYSIS
7. GLOBAL PSYCHOBIOTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Product Market Map
7.3.1. By Psychotropic Agent
7.3.2. By Form
7.3.3. By Application
7.3.4. By Region
7.4. Pricing Analysis
8. NORTH AMERICA PSYCHOBIOTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
8.2.4. By Country
8.3. Pricing Analysis
8.4. North America: Country Analysis
8.4.1. United States Psychobiotics Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value & Volume
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Psychotropic Agent
8.4.1.2.2. By Form
8.4.1.2.3. By Application
8.4.1.3. Pricing Analysis
8.4.2. Mexico Psychobiotics Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value & Volume
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Psychotropic Agent
8.4.2.2.2. By Form
8.4.2.2.3. By Application
8.4.2.3. Pricing Analysis
8.4.3. Canada Psychobiotics Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value & Volume
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Psychotropic Agent
8.4.3.2.2. By Form
8.4.3.2.3. By Application
8.4.3.3. Pricing Analysis
9. EUROPE PSYCHOBIOTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
9.2.4. By Country
9.3. Pricing Analysis
9.4. Europe: Country Analysis
9.4.1. France Psychobiotics Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value & Volume
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Psychotropic Agent
9.4.1.2.2. By Form
9.4.1.2.3. By Application
9.4.1.3. Pricing Analysis
9.4.2. Germany Psychobiotics Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value & Volume
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Psychotropic Agent
9.4.2.2.2. By Form
9.4.2.2.3. By Application
9.4.2.3. Pricing Analysis
9.4.3. United Kingdom Psychobiotics Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value & Volume
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Psychotropic Agent
9.4.3.2.2. By Form
9.4.3.2.3. By Application
9.4.3.3. Pricing Analysis
9.4.4. Italy Psychobiotics Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value & Volume
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Psychotropic Agent
9.4.4.2.2. By Form
9.4.4.2.3. By Application
9.4.4.3. Pricing Analysis
9.4.5. Spain Psychobiotics Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value & Volume
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Psychotropic Agent
9.4.5.2.2. By Form
9.4.5.2.3. By Application
9.4.5.3. Pricing Analysis
9.4.6. Sweden Psychobiotics Market Outlook
9.4.6.1. Market Size & Forecast
9.4.6.1.1. By Value & Volume
9.4.6.2. Market Share & Forecast
9.4.6.2.1. By Psychotropic Agent
9.4.6.2.2. By Form
9.4.6.2.3. By Application
9.4.6.3. Pricing Analysis
9.4.7. Poland Psychobiotics Market Outlook
9.4.7.1. Market Size & Forecast
9.4.7.1.1. By Value & Volume
9.4.7.2. Market Share & Forecast
9.4.7.2.1. By Psychotropic Agent
9.4.7.2.2. By Form
9.4.7.2.3. By Application
9.4.7.3. Pricing Analysis
9.4.8. Slovakia Psychobiotics Market Outlook
9.4.8.1. Market Size & Forecast
9.4.8.1.1. By Value & Volume
9.4.8.2. Market Share & Forecast
9.4.8.2.1. By Psychotropic Agent
9.4.8.2.2. By Form
9.4.8.2.3. By Application
9.4.8.3. Pricing Analysis
10. ASIA-PACIFIC PSYCHOBIOTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
10.2.4. By Country
10.3. Pricing Analysis
10.4. Asia-Pacific: Country Analysis
10.4.1. China Psychobiotics Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Psychotropic Agent
10.4.1.2.2. By Form
10.4.1.2.3. By Application
10.4.1.3. Pricing Analysis
10.4.2. India Psychobiotics Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Psychotropic Agent
10.4.2.2.2. By Form
10.4.2.2.3. By Application
10.4.2.3. Pricing Analysis
10.4.3. South Korea Psychobiotics Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Psychotropic Agent
10.4.3.2.2. By Form
10.4.3.2.3. By Application
10.4.3.3. Pricing Analysis
10.4.4. Japan Psychobiotics Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value & Volume
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Psychotropic Agent
10.4.4.2.2. By Form
10.4.4.2.3. By Application
10.4.4.3. Pricing Analysis
10.4.5. Australia Psychobiotics Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value & Volume
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Psychotropic Agent
10.4.5.2.2. By Form
10.4.5.2.3. By Application
10.4.5.3. Pricing Analysis
10.4.6. Taiwan Psychobiotics Market Outlook
10.4.6.1. Market Size & Forecast
10.4.6.1.1. By Value & Volume
10.4.6.2. Market Share & Forecast
10.4.6.2.1. By Psychotropic Agent
10.4.6.2.2. By Form
10.4.6.2.3. By Application
10.4.6.3. Pricing Analysis
10.4.7. Malaysia Psychobiotics Market Outlook
10.4.7.1. Market Size & Forecast
10.4.7.1.1. By Value & Volume
10.4.7.2. Market Share & Forecast
10.4.7.2.1. By Psychotropic Agent
10.4.7.2.2. By Form
10.4.7.2.3. By Application
10.4.7.3. Pricing Analysis
10.4.8. Singapore Psychobiotics Market Outlook
10.4.8.1. Market Size & Forecast
10.4.8.1.1. By Value & Volume
10.4.8.2. Market Share & Forecast
10.4.8.2.1. By Psychotropic Agent
10.4.8.2.2. By Form
10.4.8.2.3. By Application
10.4.8.3. Pricing Analysis
11. SOUTH AMERICA PSYCHOBIOTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
11.2.4. By Country
11.3. Pricing Analysis
11.4. South America: Country Analysis
11.4.1. Brazil Psychobiotics Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Psychotropic Agent
11.4.1.2.2. By Form
11.4.1.2.3. By Application
11.4.1.3. Pricing Analysis
11.4.2. Argentina Psychobiotics Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Psychotropic Agent
11.4.2.2.2. By Form
11.4.2.2.3. By Application
11.4.2.3. Pricing Analysis
11.4.3. Colombia Psychobiotics Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Psychotropic Agent
11.4.3.2.2. By Form
11.4.3.2.3. By Application
11.4.3.3. Pricing Analysis
12. MIDDLE EAST AND AFRICA PSYCHOBIOTICS MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
12.2.4. By Country
12.3. Pricing Analysis
12.4. MEA: Country Analysis
12.4.1. South Africa Psychobiotics Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Psychotropic Agent
12.4.1.2.2. By Form
12.4.1.2.3. By Application
12.4.1.3. Pricing Analysis
12.4.2. Saudi Arabia Psychobiotics Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Psychotropic Agent
12.4.2.2.2. By Form
12.4.2.2.3. By Application
12.4.2.3. Pricing Analysis
12.4.3. UAE Psychobiotics Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Psychotropic Agent
12.4.3.2.2. By Form
12.4.3.2.3. By Application
12.4.3.3. Pricing Analysis
13. MARKET DYNAMICS
13.1. Drivers
13.1.1. Increased Use of Probiotics for Anxiety and Depression
13.1.2. Surge in Subjects with Anxiety and Depression
13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
13.2. Challenges
13.2.1. Detrimental Effects on Physical Health
13.2.2. Endocrine and Metabolic Side Effects
13.2.3. Unavailability in Developing Countries and Under-Developed Countries
14. MARKET TRENDS & DEVELOPMENTS
14.1. Increasing Number of Clinical Trials
14.2. Increased Competition and Upcoming Innovations
14.3. Mergers & Acquisitions
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. InnovixLabs
15.6.2. Bened Biomedical Co., Ltd
15.6.3. Nutrimmun GmbH
15.6.4. Kerry Group Plc.
15.6.5. Sabinsa Corporation
15.6.6. Lallemand Health Solutions Inc.
15.6.7. DuPont de Nemours, Inc.
15.6.8. Uplift Food Pty Ltd.
15.6.9. Nature's Bounty Co. Ltd.
15.6.10. BioGaia Group
15.6.11. The Life Extension Foundation
15.6.12. Lifted Naturals
16. STRATEGIC RECOMMENDATIONS
